{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=temozolomide+%28TMZ%29&page=2",
    "query": {
      "intervention": "temozolomide (TMZ)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 456,
    "total_pages": 46,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=temozolomide+%28TMZ%29&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=temozolomide+%28TMZ%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-05T08:14:12.164Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00612651",
      "title": "PH I Addition of Farnesyl Transferase Inhibitor to Temozolomide for Pts w Gr 3 & 4 Malignant Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gliosarcoma",
        "Glioblastoma",
        "Anaplastic Astrocytoma"
      ],
      "interventions": [
        {
          "name": "Temodar and SCH 66336",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2005-10",
      "completion_date": "2011-06",
      "has_results": false,
      "last_update_posted_date": "2013-02-20",
      "last_synced_at": "2026-10-05T08:14:12.164Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00612651"
    },
    {
      "nct_id": "NCT01217437",
      "title": "Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Central Nervous System Neoplasm",
        "Pineoblastoma",
        "Recurrent Medulloblastoma",
        "Recurrent Primitive Neuroectodermal Tumor",
        "Refractory Medulloblastoma",
        "Refractory Peripheral Primitive Neuroectodermal Tumor"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Irinotecan Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 108,
      "start_date": "2010-11-22",
      "completion_date": "2021-06-30",
      "has_results": true,
      "last_update_posted_date": "2021-07-23",
      "last_synced_at": "2026-10-05T08:14:12.164Z",
      "location_count": 136,
      "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 103 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01217437"
    },
    {
      "nct_id": "NCT00313729",
      "title": "Temozolomide in Treating Patients With Low-Grade Glioma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "CNS Tumor, Adult"
      ],
      "interventions": [
        {
          "name": "temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 120,
      "start_date": "1999-05",
      "completion_date": "2017-06-12",
      "has_results": true,
      "last_update_posted_date": "2019-02-07",
      "last_synced_at": "2026-10-05T08:14:12.164Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00313729"
    },
    {
      "nct_id": "NCT02340156",
      "title": "Phase II Study of Combined Temozolomide and SGT-53 for Treatment of Recurrent Glioblastoma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "RECURRENT GLIOBLASTOMA"
      ],
      "interventions": [
        {
          "name": "SGT-53",
          "type": "GENETIC"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "SynerGene Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1,
      "start_date": "2014-12",
      "completion_date": "2018-11",
      "has_results": true,
      "last_update_posted_date": "2021-03-03",
      "last_synced_at": "2026-10-05T08:14:12.164Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02340156"
    },
    {
      "nct_id": "NCT07326566",
      "title": "Study of Silevertinib With Temozolomide for the Treatment of Newly Diagnosed GBM With Unmethylated MGMT and EGFRvIII",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma (GBM)",
        "Newly Diagnosed Glioblastoma",
        "GBM",
        "Glioblastoma Multiforme (GBM)",
        "Glioma",
        "Central Nervous System Diseases",
        "Brain Cancer"
      ],
      "interventions": [
        {
          "name": "silevertinib in combination with temozolomide",
          "type": "DRUG"
        },
        {
          "name": "temozolomide (TMZ)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Black Diamond Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 162,
      "start_date": "2026-05-05",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2026-09-28",
      "last_synced_at": "2026-10-05T08:14:12.164Z",
      "location_count": 31,
      "location_summary": "Birmingham, Alabama • Springdale, Arkansas • La Jolla, California + 26 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07326566"
    },
    {
      "nct_id": "NCT01991977",
      "title": "18F-DOPA-PET in Finding Tumors in Patients With Newly Diagnosed Gliomas Undergoing Radiation Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Malignant Glioma"
      ],
      "interventions": [
        {
          "name": "Diffusion Weighted Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Fluorine F 18 Fluorodopa",
          "type": "DRUG"
        },
        {
          "name": "Intensity-Modulated Radiation Therapy",
          "type": "RADIATION"
        },
        {
          "name": "Perfusion Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 91,
      "start_date": "2013-12",
      "completion_date": "2024-07-15",
      "has_results": true,
      "last_update_posted_date": "2025-10-20",
      "last_synced_at": "2026-10-05T08:14:12.164Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01991977"
    },
    {
      "nct_id": "NCT00027742",
      "title": "Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Intraocular Melanoma",
        "Melanoma (Skin)"
      ],
      "interventions": [
        {
          "name": "pegylated interferon alfa",
          "type": "BIOLOGICAL"
        },
        {
          "name": "temozolomide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": null,
      "start_date": "2001-05",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2013-06-05",
      "last_synced_at": "2026-10-05T08:14:12.164Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00027742"
    },
    {
      "nct_id": "NCT00597402",
      "title": "Avastin in Combination With Radiation (XRT) & Temozolomide, Followed by Avastin, Temozolomide and Irinotecan for Glioblastoma (GBM) and Gliosarcomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Glioblastoma",
        "Gliosarcoma",
        "Brain Tumor"
      ],
      "interventions": [
        {
          "name": "Avastin",
          "type": "DRUG"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Radiation Therapy (XRT)",
          "type": "RADIATION"
        },
        {
          "name": "Irinotecan",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION"
      ],
      "sponsor": "Duke University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 125,
      "start_date": "2007-07",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2014-05-07",
      "last_synced_at": "2026-10-05T08:14:12.164Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00597402"
    },
    {
      "nct_id": "NCT00610571",
      "title": "Ph I Oral Topotecan and Temozolomide for Patients With Malignant Gliomas",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Glioblastoma",
        "Gliosarcoma",
        "Anaplastic Astrocytoma"
      ],
      "interventions": [
        {
          "name": "Oral Topotecan and Temodar",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Katy Peters",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 62,
      "start_date": "2004-04",
      "completion_date": "2012-04",
      "has_results": false,
      "last_update_posted_date": "2013-10-25",
      "last_synced_at": "2026-10-05T08:14:12.164Z",
      "location_count": 1,
      "location_summary": "Durham, North Carolina",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00610571"
    },
    {
      "nct_id": "NCT05691491",
      "title": "Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Advanced Microsatellite Stable Colorectal Carcinoma",
        "Hematopoietic and Lymphatic System Neoplasm",
        "Metastatic Malignant Solid Neoplasm",
        "Metastatic Microsatellite Stable Colorectal Carcinoma",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy Procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Temozolomide",
          "type": "DRUG"
        },
        {
          "name": "Tuvusertib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 42,
      "start_date": "2023-09-28",
      "completion_date": "2027-03-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-31",
      "last_synced_at": "2026-10-05T08:14:12.164Z",
      "location_count": 23,
      "location_summary": "Irvine, California • La Jolla, California • Orange, California + 17 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Trumbull",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05691491"
    }
  ]
}